A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Platzbecker, U, Symeonidis, A, Oliva, E N, Goede, J S, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596208/
https://www.ncbi.nlm.nih.gov/pubmed/28626220
http://dx.doi.org/10.1038/leu.2017.192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596208/
https://www.ncbi.nlm.nih.gov/pubmed/28626220
http://dx.doi.org/10.1038/leu.2017.192

Ejemplares similares